A contemporary viewpoint on 'aspirin resistance'

Annals of Medicine

Volumn 44, Issue 8, 2012, Pages 773-783

  Kuzniatsova, Nadzeya ^a   Shantsila, Eduard ^a   Blann, Andrew ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Aspirin resistance; Atherothrombosis; Cardiovascular events; Inflammation; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; NONSTEROID ANTIINFLAMMATORY AGENT; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG DOSE ESCALATION; DRUG TREATMENT FAILURE; HUMAN; INFLAMMATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT RESPONSE;

ASPIRIN; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 84869490240     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.605388     Document Type: Review

References (128)

1. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Th romb Haemost. 2003;1:1710-3.
2. C attaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Th romb Vasc Biol. 2004;24:1980-7.
3. W eber AA, Przytulski B, Schanz A, Hohlfeld T, Schrr K. Towards a definition of aspirin resistance: a typological approach. Platelets. 2002;13:37-40.
4. Pulcinelli FM, Riondino S. More on aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm. J Th romb Haemost. 2006;4:485-7.
5. K uliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Th rombosis of the European Society of Cardiology. Eur Heart J. 2009;30: 426-35.
6. B hatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15-28.
7. B en-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol. 2009;104:227-33.
8. S erebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246-51.
9. A ngiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramrez C, SabatM, Jimenez-Quevedo P, et al. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel aft er percutaneous coronary intervention. Am J Cardiol. 2006;97:38-43.
10. A ngiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramrez C, Cavallari U, Trabetti E, et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol. 2005;96:1095-9.
11. G urbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the eff ect of pretreatment platelet reactivity. Circulation. 2003;107:2908-13.
12. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206-11.
13. R eilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180-6.
14. M aree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;46:1258-63.
15. M inuz P, Fumagalli L, Gaino S, Tommasoli RM, Degan M, Cavallini C, et al. Rapid stimulation of tyrosine phosphorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets. Biochem J. 2006;400:127-34.
16. Bares BJ, Teth-Zs Smboki E, Vargov K, Laszl A, Masszi T, Kerecsen G, et al. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Th romb Haemost. 2008;100:829-38.
17. W illiams MS, Kickler TS, Vaidya D, Ng' a lla LS, Bush DE. Evaluation of platelet function in aspirin treated patients with CAD. J Th romb Th rombolysis. 2006;21:241-7.
18. F ontana P, Nolli S, Reber G, de Moerloose P. Biological eff ects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Th romb Haemost. 2006;4:813-9.
19. F relinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006;113:2888-96.
20. H edegaard SS, Hvas AM, Grove EL, Refsgaard J, Rocca B, Dava G, et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease aft er low-dose aspirin administration. Th romb Res. 2009;124:96-100.
21. O hmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Th romb Haemost. 2006;4:1271-8.
22. P atrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest. 1986;77:590-4.
23. C hiabrando C, Rivoltella L, Martelli L, Valzacchi S, Fanelli R. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects. Biochim Biophys Acta. 1992;1133:247-54.
24. C atella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Th romb Res. 1987;47:647-56.
25. M aclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Th romb Haemost. 1998;79:691-705.
26. K arim S, Habib A, Luvy-Toledano S, Maclouf J. Cyclooxygenase-1 and-2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 1996;271:12042-8.
27. W eber AA, Zimmermann KC, Meyer-Kirchrath J, Schrr K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999;353:900.
28. M ichelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:e489-93.
29. H arrison P, Frelinger AL 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug eff ects in the laboratory. Th romb Res. 2007;120: 323-36.
30. C attaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Th romb Haemost. 2007;5 Suppl 1:230-7.
31. C oleman JL, Wang JC, Simon DI. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA System. Point Care. 2004;3:77-82.
32. S chmitz G, Rothe G, Ruf A, Barlage S, Tsche D, Clemetson KJ, et al. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Th romb Haemost. 1998;79:885-96.
33. L ordkipanidz M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702-8.
34. G rove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Th romb Haemost. 2010;103:1245-53.
35. M uir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart. 2009;95:1225-9.
36. C hakroun T, Addad F, Abderazek F, Ben-Farhat M, Hamdi S, Gamra H, et al. Screening for aspirin resistance in stable coronary artery patients by three diff erent tests. Th romb Res. 2007;121:413-8.
37. C ampbell CL, Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance? J Th romb Haemost. 2005;3:665-9.
38. H ovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007;153:175-81.
39. G uthikonda S, Mangalpally K, Vaduganathan M, Patel R, Delao T, Bergeron AL, et al. Increased platelet sensitivity among individuals with aspirin resistance-platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Th romb Haemost. 2008;100:83-9.
40. D ichiara J, Bliden KP, Tantry US, Chaganti SK, Kreutz RP, Gesheff TB, et al. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets. 2007;18: 414-23.
41. Z immermann N, Hohlfeld T. Clinical implications of aspirin resistance. Th romb Haemost. 2008;100:379-90.
42. K rasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin' resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195-8.
43. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and metaanalysis. Arch Intern Med. 2007;167:1593-9.
44. C rescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer(PFA)-100. A systematic review. Th romb Haemost. 2008;99:14-26.
45. R eny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Th romb Haemost. 2008;6:444-50.
46. Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, et al. Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirintreated patients presenting for cardiac catheterization. Circulation. 2009;120:2586-96.
47. E ikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-5.
48. Eikelboom JW, Hankey GJ, Th om J, Bhatt DL, Steg PG, Montalescot G, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and eff ect on cardiovascular risk. Circulation. 2008;118:1705-12.
49. H alushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective eff ects of aspirin? Could it be thromboxane A2? Circulation. 2002;105:1620-2.
50. B reet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303:754-62.
51. H ankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367 606-17.
52. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Th romb Haemost. 2010;104:279-86.
53. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961-5.
54. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Th romb Haemost. 1997;78:1003-7.
55. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47:27-33.
56. G ori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008;52:734-9.
57. C uisset T, Frere C, Quilici J, Morange PE, Camoin L, Bali L, et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Th romb Res. 2009;123:597-603.
58. F ontana P, Berdagu P, Castelli C, Nolli S, Barazer I, Fabbro-Peray P, et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Th romb Haemost. 2010;8:2614-23.
59. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51:1829-43.
60. H anjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev. 2006;14:18-25.
61. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005;142:370-80.
62. U ndas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007;109:2285-92.
63. G oodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66:222-32.
64. S zczeklik A, Musiał J, Undas A, Sanak M, Nizankowski R. Aspirin resistance. Pharmacol Rep. 2005;57 Suppl:33-41.
65. S chwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin aft er healing of myocardial infarction. Am J Cardiol. 2005;95:973-5.
66. D elvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114:2367-74.
67. V an Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol. 2009;85: 195-204.
68. J ennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Th romb Haemost. 2009;102:248-57.
69. S hantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Th romb Haemost. 2009;102:916-24.
70. A ssinger A, Koller F, Schmid W, Zellner M, Babeluk R, Koller E, et al. Specific binding of hypochlorite-oxidized HDL to platelet CD36 triggers proinflammatory and procoagulant eff ects. Atherosclerosis. 2010;212:153-60.
71. A ssinger A, Koller F, Schmid W, Zellner M, Koller E, Volf I. Hypochloriteoxidized LDL induces intraplatelet ROS formation and surface exposure of CD40L-A prominent role of CD36. Atherosclerosis. 2010;213: 129-34.
72. P odrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086-95.
73. A ntczak AJ, Singh N, Gay SR, Worth RG. IgG-complex stimulated platelets: a source of sCD40L and RANTES in initiation of inflammatory cascade. Cell Immunol. 2010;263:129-33.
74. C hen WH, Lee PY, Ng W, Kwok JY, Cheng X, Lee SW, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol. 2005;96: 760-3.
75. C harron T, Jaff e R, Segev A, Bang KW, Qiang B, Sparkes JD, et al. Eff ects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow. Th romb Res. 2010;126: 50-5.
76. F araday N, Yanek LR, Vaidya D, Kral B, Qayyum R, Herrera-Galeano JE, et al. Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. Th romb Res. 2009;124: 311-7.
77. T antry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Th rombotic RIsk Progression (TRIP) study. Platelets. 2010;21:360-7.
78. Jurk K, Ritter MA, Schriek C, Van Aken H, Droste DW, Ringelstein EB, et al. Activated monocytes capture platelets for heterotypic association in patients with severe carotid artery stenosis. Th romb Haemost. 2010;103:1193-202.
79. Z alai CV, Kolodziejczyk MD, Pilarski L, Christov A, Nation PN, Lundstrom-Hobman M, et al. Increased circulating monocyte activation in patients with unstable coronary syndromes. J Am Coll Cardiol. 2001;38:1340-7.
80. L iuzzo G, Angiolillo DJ, Buff on A, Rizzello V, Colizzi C, Ginnetti F, et al. Enhanced response of blood monocytes to in vitro lipopolysaccharidechallenge in patients with recurrent unstable angina. Circulation. 2001;103:2236-41.
81. M angiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, et al. High residual platelet reactivity aft er clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2010;3:35-40.
82. S mith T, Dhunnoo G, Mohan I, Charlton-Menys V. A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease. Platelets. 2007;18:245-8.
83. L inden MD, Furman MI, Frelinger AL 3rd, Fox ML, Barnard MR, Li Y, et al. Indices of platelet activation and the stability of coronary artery disease. J Th romb Haemost. 2007;5:761-5.
84. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392-7.
85. C ampo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol. 2006;48:2178-85.
86. Geisler T, Kapp M, Ghring-Frischholz K, Daub K, Dach C, Bigalke B, et al. Residual platelet activity is increased in clopidogrel-and ASAtreated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart. 2008;94:743-7.
87. G ori AM, Cesari F, Marcucci R, Giusti B, Paniccia R, Antonucci E, et al. The balance between pro-and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis. 2009;202:255-62.
88. B ernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Th romb Haemost. 2010;104:1193-200.
89. E lsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, et al. The influence of clinical characteristics, laboratory and inflammatory markers on' high on-treatment platelet reactivity' as measured with diff erent platelet function tests. Th romb Haemost. 2009;102:719-27.
90. C hakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol. 2004;124:80-5.
91. E lesber AA, Conover CA, Denktas AE, Lennon RJ, Holmes DR Jr, Overgaard MT, et al. Prognostic value of circulating pregnancyassociated plasma protein levels in patients with chronic stable angina. Eur Heart J. 2006;27:1678-84.
92. F errante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, et al. Association between C-reactive protein and angiographic restenosis aft er bare metal stents: an updated and comprehensive metaanalysis of 2747 patients. Cardiovasc Revasc Med. 2008;9:156-65.
93. H uang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen JW, et al. Usefulness of combined high-sensitive C-reactive protein and N-terminalprobrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease. Coron Artery Dis. 2008;19:187-93.
94. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, et al. Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur Heart J. 2008;29:1241-9.
95. D anesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-97.
96. W ang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-9.
97. D osh K, Berger PB, Marso S, van Lente F, Brennan DM, Charnigo R, et al. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events aft er percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Circ Cardiovasc Interv. 2009;2:503-12.
98. R idker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.
99. B ordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N, et al. Eff ect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol. 2010;13:56-62.
100. U nek IT, Bayraktar F, Solmaz D, Ellidokuz H, Yuksel F, Sisman AR, et al. Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism. 2010;59:305-13.
101. S chneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525-7.
102. Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response aft er clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Th romb Haemost. 2008;100:76-82.
103. K aplar M, Kappelmayer J, Veszpremi A, Szabo K, Udvardy M. The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets. 2001;12:419-22.
104. D anenberg HD, Kantak N, Grad E, Swaminathan RV, Lotan C, Edelman ER. C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur J Haematol. 2007;78:246-52.
105. K onieczkowski M, Skrinska VA. Increased synthesis of thromboxane A(2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids. 2001;65:133-8.
106. B artolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98:746-50.
107. O gawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-41.
108. B elch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al.; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
109. M ichelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Th rombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Th romb Haemost. 2005;3:1309-11.
110. S mith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:216-35.
111. E uropean Association for Percutaneous Cardiovascular Interventions; Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Th oracic Surgery (EACTS). Eur Heart J. 2010;31:2501-55.
112. O ptimizing Aspirin and Clopidogrel Th erapy (BOchum CLopidogrel and Aspirin Plan) (BOCLAplan). ClinicalTrials.gov Identifier NCT 01212302. Available at: clinicaltrials.gov (accessed December 2010).
113. A spirin Non-Responsiveness and Clopidogrel Endpoint Trial (ASCET). ClinicalTrials.gov Identifier NCT 00222261. Available at: clinicaltrials. gov (accessed December 2010).
114. A spirin Resistance and Percutaneous Coronary Intervention (PCI) (RESIST). ClinicalTrials.gov Identifier NCT 01103440. Available at: clinicaltrials.gov (accessed December 2010).
115. Dual Antiplatelet Th erapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Graft ing. ClinicalTrials.gov Identifier NCT 01159639. Available at: clinicaltrials.gov (accessed December 2010).
116. Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Th erapy (ARCTIC). ClinicalTrials.gov Identifier NCT 00827411. Available at: clinicaltrials.gov (accessed December 2010).
117. Th rombElastoGraphic Coagulation Status and Antiplatelet Th erapy Aft er Coronary Artery Bypass Graft Surgery (TEG-CABG). Clinical-Trials.gov Identifier NCT 01046942. Available at: clinicaltrials.gov (accessed December 2010).
118. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (Aspirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J. 2004;38: 353-6.
119. A SCET: Single antiplatelet therapies compared in stable CAD. Available at: http://www.theheart.org/article/1157257.do accessed 12 April 2011
120. N eubauer H, Kaiser AF, Endres HG, Kruger JC, Engelhardt A, Lask S, et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-Th e BOchum CLopidogrel and Aspirin Plan (BOCLAPlan) to improve antiplatelet therapy. BMC Med. 2011;9:3.
121. The ITALIC Study: Is Th ere A Life for Drug-eluting Stents (DES) Aft er Discontinuation of Clopidogrel. ClinicalTrials.gov Identifier NCT00780156. Available at: clinicaltrials.gov (accessed May 2011).
122. U ndas A, Siudak Z, Topr-M d ry R, Leniak M, Tracz W. Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation. Int J Cardiol. 2010 Oct 28 (Epub ahead of print).
123. Tirnaksiz E, Pamukcu B, Oflaz H, Nisanci Y. Eff ect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J Th romb Th rombolysis. 2009;27:24-8.
124. S antos MT, Fuset MP, Ruano M, Moscard A, Valles J. Eff ect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Am J Cardiol. 2009;104:1618-23.
125. L arson MK, Ashmore JH, Harris KA, Vogelaar JL, Pottala JV, Sprehe M, et al. Eff ects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Th romb Haemost. 2008;100:634-41.
126. L ev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, et al. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol. 2010;55:114-21.
127. Gajos G, Rostoff P, Undas A, Piwowarska W. Eff ects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGAPCI (OMEGA-3 fatty acids aft er pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol. 2010;55:1671-8.
128. Muhlestein JB. Eff ect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Th romb Haemost. 2010;103:71-82.